Company intelligence / Profile preview

Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.

Shanghai, Shanghai, Chinapharmaceutical-technology.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has multiple products in clinical development, with SSGJ-608 (anti-IL-17A monoclonal antibody) having completed Phase 3 clinical study for psoriasis with data expected in Q4 2023. The company plans to submit an application for listing in 2024. Other products include SSGJ-707 (PD-1 x VEGF bispecific antibody) and HBT-708 in Phase 1 for advanced malignant solid neoplasms[1][9].

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Bispecific antibodyBiological productsMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

HBT-708

Beyond the preview

Go deeper on Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd..

Explore the full profile